VON ESCHENBACH
Kenneth Lambert  /  AP
 Dr. Andrew von Eschenbach, former head of the National Cancer Institute, has been designated as the acting director of the Food and Drug Administration.
updated 9/26/2005 7:34:37 AM ET 2005-09-26T11:34:37

The incoming head of the Food and Drug Administration says the agency must stay on top of emerging discoveries into the mechanisms of disease that may lead to new treatments that can be tailored to individual patients.

Dr. Andrew C. von Eschenbach, tapped by President Bush to at least temporarily head the regulatory agency, said Sunday that recent research will lead to a new kind of health care.

“We are discovering so much about diseases like cancer at the molecular level,” von Eschenbach, a urologic surgeon by training, said in an interview with The Associated Press.

Based on these understandings, physicians will be able to devise treatments more effectively matched to a specific patient and his or her condition, he said. That’s a fundamental shift: Doctors now treat illnesses based primarily on how well other people have responded to a given treatment.

Von Eschenbach has a reputation for optimism. As head of the National Cancer Institute, he outlined an ambitious goal of eliminating suffering and death due to cancer and turning it into a manageable disease by 2015 — an aim regarded by some as unlikely.

But von Eschenbach has seen cancer from both sides, having survived three diagnoses: melanoma, prostate cancer and basal cell carcinoma.

Von Eschenbach said he will stay in his post at the institute, which is the government’s lead agency in researching cancer treatments, while running the FDA. He gave no indication whether he expected to be nominated as permanent chief of the FDA.

He replaces Commissioner Lester Crawford, out only two months after the Senate confirmed him for the post. Crawford had functioned as acting head for more than year.

'Accelerate' new treatments
Crawford’s surprise resignation Friday gave no specific reason for his departure. His tenure was marked by increasing criticism of the agency by those who contended it had become more interested in politics or benefiting drug companies than in its mission to protect consumers.

Von Eschenbach declined to discuss in detail specific cases that have led to criticism of the FDA. They include Vioxx, a class of painkiller lately tied to heart problems, and Plan B, an emergency, morning-after contraceptive that the FDA has yet to approve for over-the-counter sales, despite assurances it is safe.

Von Eschenbach had only praise for his colleagues at the FDA, calling the agency the “gold standard” for food and health care regulation.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

“I have an enormous amount of respect, admiration and appreciation for them,” he said, and will continue many of his predecessors’ initiatives while looking for ways to improve agency operations.

Von Eschenbach also discussed the perpetual challenge for the FDA: speeding new treatments to the market while ensuring they are safe. Sometimes those values are in conflict, as pressure from drug companies and patients to make new treatments available run up against incomplete or ambiguous safety data.

“I believe very strongly that science has to drive and is the driver of our knowledge and our understanding, and therefore of our decisions,” he said. “Where science is incomplete, we continue to believe that under any circumstances, do no harm.”

But with new treatments, von Eschenbach said: “I believe it’s still important to ask the question, ’How can we accelerate the timeline? How can we make certain we are getting these interventions to the patients as quickly as possible?”’

The Philadelphia native served as chief academic officer of the University of Texas M.D. Anderson Cancer Center in Houston before taking over the National Cancer Institute in 2002.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments